The global intraoperative radiation therapy systems market is estimated to be valued at USD 68.8 million in 2025 and is projected to reach USD 144.6 million by 2035, registering a compound annual growth rate (CAGR) of 7.7% over the forecast period.
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 68.8 Million |
| Industry Value (2035F) | USD 144.6 Million |
| CAGR (2025 to 2035) | 7.7% |
The Intraoperative Radiation Therapy (IORT) Systems Market is experiencing renewed momentum as healthcare systems globally prioritize precision oncology and shorter radiation cycles. As of 2025, IORT systems are increasingly being incorporated into hybrid operating suites due to their ability to deliver high-dose, localized radiation at the time of tumor resection, minimizing damage to surrounding healthy tissues. This approach is particularly gaining traction in breast, colorectal, pancreatic, and gynecologic cancer interventions where organ preservation and surgical precision are critical.
Clinical trials and multicenter collaborations are validating IORT as a cost-effective alternative or complement to external beam radiation therapy (EBRT), especially in early-stage cancers and palliative scenarios. Additionally, technology convergence with portable linear accelerators, real-time dosimetry, and 3D surgical navigation is expanding IORT’s intraoperative utility. Regulatory agencies are also supporting these innovations through expedited review pathways, especially in markets with high unmet needs in rural and underserved surgical oncology units.
Key players shaping the IORT Systems market include Carl Zeiss Meditec AG, Sordina IORT Technologies, Eckert & Ziegler BEBIG, and GMV Innovating Solutions. These companies are actively enhancing system portability, miniaturization, and integration with surgical oncology workflows. In April 2025, Carl Zeiss Meditec received clearance form USFDA to ZEISS Medical’s INTRABEAM 700, an advanced intraoperative radiotherapy (IORT) platform developed to deliver precise, low-energy X-ray radiation directly to tumor beds during surgery.
In 2025, Christian Schwedes, head of the Neuro- and Spine Surgery Sector at ZEISS, stated: “Based on our established INTRABEAM platform, the newly developed ZEISS INTRABEAM 700 marks the next major step on our path to shaping the oncology workflows of tomorrow."
This innovation is driving broader adoption in both high-volume academic centers and mid-sized surgical oncology units. Simultaneously, GMV is expanding its radiotherapy software to support real-time intraoperative image registration, and BEBIG is working on enhancing its mobile HDR brachytherapy solutions. Manufacturers are also forming strategic alliances with surgical device OEMs to enable seamless workflow integration, which is vital for improving surgical throughput and radiation accuracy.
North America currently dominates the global IORT systems market due to its established cancer centers, access to capital equipment funding, and favourable reimbursement pathways, particularly in the USA Tertiary oncology hospitals are rapidly incorporating IORT within breast and colorectal cancer programs as part of accelerated treatment pathways. The American Society for Radiation Oncology (ASTRO) continues to support IORT clinical studies through joint initiatives with surgical societies, influencing broader procedural adoption. Furthermore, collaborations between IORT system manufacturers and private oncology chains are facilitating the integration of mobile IORT units in ambulatory surgical centers.
Europe is emerging as a high-opportunity market, especially in Germany, Italy, Spain, and the Nordics, where IORT is increasingly embedded in national cancer care protocols. Germany hosts one of the largest IORT procedural volumes globally, aided by early adoption and strong reimbursement from statutory insurers.
Meanwhile, Spain and Italy have increased funding for IORT pilot programs as part of public oncology system reforms. EU Horizon programs are supporting university-hospital consortia to test IORT in advanced gynaecological and pancreatic cancer settings. In the Nordics, interest is growing in mobile IORT units for decentralized hospitals with limited access to full-scale radiotherapy infrastructure.
The breast cancer has dominated the market by indication holds maximum share of 42.8% in the year 2025. This trend has been primarily influenced by the growing preference for IORT during breast-conserving surgeries, especially for early-stage and low-risk tumours. The adoption of IORT for breast cancer treatment has been accelerated by its ability to deliver targeted radiation intraoperatively, significantly reducing treatment time from several weeks to a single session.
Clinical advantages such as minimized radiation exposure to surrounding healthy tissues and reduced recurrence rates have been supported by ongoing clinical trials and peer-reviewed publications. Moreover, rising awareness campaigns, updated NCCN guidelines, and the growing global incidence of breast cancer-particularly in aging female populations-have facilitated wider deployment of IORT solutions.
Increased reimbursement approvals for early breast cancer procedures utilizing IORT across developed economies have also reinforced its commercial uptake. As a result, breast cancer has emerged as the key revenue-generating segment, supported by strong clinical validation and demand-side preference.
Hospitals have remained the primary end-user segment for intraoperative radiation therapy systems, contributing 63.6% to the market revenue in 2025. This dominance has been attributed to the comprehensive infrastructure, specialized surgical teams, and regulatory certifications required to safely deploy IORT technology, which are predominantly housed within hospital settings.
Additionally, the availability of hybrid operating rooms, integrated radiology equipment, and post-operative monitoring facilities in hospitals has enhanced the procedural efficacy and clinical outcomes of IORT, making hospitals the preferred point of care. Institutional funding capabilities, procurement of high-cost capital equipment, and ongoing investments in oncology service expansion have further enabled hospitals to adopt IORT systems.
Collaborative research programs between academic hospitals and technology providers have also facilitated clinical integration and real-world validation. Moreover, the influx of cancer patients seeking specialized care, particularly in tertiary and quaternary care centers, has ensured that hospitals remain the central node for IORT delivery, reinforcing their market leadership among end users.
One of The Significant Restraints for The Intraoperative Radiation Therapy Market Is the Limited Scope of Regulatory Approvals
The high initial capital expenditure for equipment purchase and operating room renovations is one of the major restraints for intraoperative radiation therapy systems market. Many of these systems also require radiation shielding or integration with surgical suites, making them hard to adopt in centers without an existing radiotherapy infrastructure.
Moreover, in the case of multidisciplinary teams, which also include radiation oncologists, physicists, and surgeons, specific training must be set up, leading to an operational learning curve. In some countries, reimbursement for intraoperative radiation therapy systems is limited, preventing more widespread use. Variability in clinical guidelines and long-term outcome data across cancer types may contribute to physician hesitancy and limit adoption outside of well-established use cases, such as early-stage breast cancer.
The Increasing Shift Toward Personalized Oncology Treatments Presents a Significant Opportunity
The market still has solid opportunities. The advancement of small, mobile IORT systems with minimal shielding requirements makes it possible for small hospitals and ambulatory centers to implement sophisticated radiotherapy techniques. Clinical data are broadening IORT’s indications to include head and neck, pancreatic, and colorectal cancers, driving new demand across oncology sub-specialties. Its combination with artificial intelligence and image-guided surgery platforms is improving accuracy and customization of radiation dosing.
Moreover, the reimbursement frameworks in expanding economies such as USA, Germany, and Japan are further bolstering access to intraoperative radiation procedures. Partnerships between device manufacturers, the research community, and cancer centers are speeding innovation and real-world clinical validation.
Expansion of Breast Cancer Applications
Accelerated acceptance is being seen for intraoperative radiation therapy in early-stage breast cancer treatment, thus challenging traditional external bean radiation therapy. By delivering a high concentration of radiation directly to the tumor bed during lumpectomy, IORT averts radiation to the surrounding tissues and also does away with the need for postoperative cycles of radiation. This one-time procedure affords more comfort to the patients while cutting down on hospital resources.
Technologies like the Intrabeam and Mobetron have become popular with the oncologists due to the improved clinical outcomes allele-related with lower local and systemic recurrence, thereby engaging the breast-conserving surgeries always backed by IORT. IORT's role in bettering outcomes and making the treatment process smoother is being gradually consolidated because of the evolution of value-based care.
Convergence of IORT with Robotic and Image-Guided Surgery
One pivotal trend shaping the IORT market is the combination of IORT with robotic surgery and modern intraoperative imaging technologies. Robotic platforms enhance the precision of surgery and access to tumors located inside or close to complex anatomy. At the same time, intraoperative radiation delivery delivers high-concentrated radiation doses to the tumor bed during the surgical procedure. This union favors a cancer-oriented customized, minimally invasive approach.
Leading cancer centers are adopting advanced hybrid operating theaters with the mobile units of intraoperative radiation therapy next to them, fueled by the inclusion in operative modalities of Intra-OP MRI or CT. Focused on the advancement of precise targeting and associated outcomes, the convergence herein signifies reduced triggers for lengthy postoperation postoperative therapies that support the development toward precision medicine and efficient cancer care.
Market Outlook
Due to an established healthcare system with high acceptance of novel cancer therapies, the United States leads the worldwide IORT systems market. The large burden of cancers like breast cancer and gastroenterological cancers has generated continuous demand for precise and effective treatment modalities such as IORT.
USA medical facilities, including large hospitals and dedicated oncology centers, are also seamlessly outfitted with cutting edge intraoperative radiation therapy systems under favorable reimbursement conditions and with high investments in oncology technology. The emphasis on personalized and targeted cancer treatment, extensive research activities and collaborations between industry and academia keep fuelling the market ahead. Expansion of specialty cancer centers further strengthens the country’s leadership in this area.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 2.5% |
Market Outlook
The market has been dominated by Germany in the Europe, establishing the backbone for the intraoperative radiation therapy market in the region and integration of intraoperative radiation therapy systems in best-performing hospitals, and cancer care units. The country’s attention to clinical research and patient safety have helped enable development and use of advanced radiation technologies.
There is no shortage of evidence supporting the effectiveness of intraoperative radiation therapy systems in multiple cancer indications backed by extensive clinical trials conducted by German healthcare institutions. Partnerships with academic institutions also play a role in expanding the breadth of innovation in the space. As a consequence of a well-structured healthcare system and encouraging government policies, Germany is predicted to continue to be one of the prominent marketplaces for intraoperative radiation therapy systems in the region.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Germany | 3.7% |
Market Outlook
Japan has a growing intraoperative radiation therapy systems market owing to its precision medicine preference and technological operational excellence. Its use with breast and abdominal cancers is working its way into oncology protocols at many of the top medical centers in the country. Researchers in Japan are investigating the combination of IORT with standard therapies and the extent of its effect in improving clinical outcomes and decreasing the rate of tumor recurrence.
Government assistance for cancer control programs and the nation’s focus on minimally invasive and patient-centered care are advantageous for the market. As a result of an aging population and increasing instances of cancer, Japan is expected to experience continuous progress in the adoption of intraoperative radiation therapy systems in its healthcare facilities.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.4% |
Market Outlook
The intraoperative radiation therapy systems market is segmented based on technology, product type, application, and end use. IORT is becoming an integral part of comprehensive oncology programs at the nations top hospitals and cancer institutes. Oncologists and surgeons, increasingly aware of a benefit of, say, delivering targeted radiation during surgery - minimizing exposure to healthy tissues, shortening overall treatment time - are looking to innovative imaging technologies that promise to integrate slices of the genome into the surgical battlefield.
The growth is attributed to the increasing emphasis on equipping public and private healthcare providers with advanced radiation therapy systems. International partnerships with med-tech firms and active involvement in global cancer care projects only speed up adoption of systems for intraoperative radiation therapy across leading Indian metros.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| India | 6.6% |
Market Outlook
The Brazil market for intraoperative radiation therapy systems is being driven by an upgrade in healthcare infrastructure and a growing emphasis on cancer treatment. Intraoperative radiation therapy systems in the country are slowly being merged into the standard therapeutic guidelines of tertiary hospitals and oncology centers. In recent years, intraoperative radiation therapy systems have gained popularity in Brazil due to their advantages, such as reducing hospitalization and maintaining local control of tumors.
Policymaking enforced by the government to widen access to quality cancer treatment is propelling adoption, particularly in urban areas. Brazil is already making in-roads into the IORT sector and as the training programs improve and further advantages are recognized, it is likely to become the leading player in Latin America, with potential for broader availability across public and private healthcare.
Market Growth Factors
Market Forecast
| Country | CAGR (2025 to 2035) |
|---|---|
| Brazil | 4.4% |
The intraoperative radiation therapy systems market is on a slow steady rise, given the increasing burden of cancers all over the globe, greater preference for precision treatment modalities, and technological advancements in mobile radiation systems. Intraoperative radiation therapy allows directing the radiation to the working site and avoiding normal structures, reducing the need for post-operative radiotherapy.
The market is moderately consolidated, with the existence of very few players monopolizing specific segments such as breast, rectal, and head and neck cancers. North America and Europe occupy major market shares while Asia-Pacific is emerging as a high-growth region with an expanding oncology infrastructure.
Brain tumors, breast cancer, gastrointestinal tumors, head & neck tumors, skin cancer, spinal metastases, others.
Hospitals, specialty clinics, ambulatory & surgical centers and others.
North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa.
The global intraoperative radiation therapy systems industry is projected to witness CAGR of 7.7% between 2025 and 2035.
The global intraoperative radiation therapy systems industry stood at USD 63.9 million in 2024.
The global intraoperative radiation therapy systems industry is anticipated to reach USD 144.6 million by 2035 end.
China is expected to show a CAGR of 7.2% in the assessment period.
The key players operating in the global intraoperative radiation therapy systems industry are Carl Zeiss, Meditec AG, IntraOp Medical Corporation, Elekta AB, Eckert & Ziegler, Ariane Medical Systems Ltd., Sordina IORT Technologies, iCAD, Inc., GMV Innovating Solutions, Isoray, Inc., Sensus Healthcare and Others.
Explore Similar Insights
Intraoperative Radiation Therapy Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
